John Butler, Akebia CEO
Otsuka pays Akebia $55M to formally end vadadustat partnership, waving goodbye to the $1B deal
Last month, Otsuka decided to call off its vadadustat collaboration with Akebia Therapeutics after the drug was rejected at the FDA. Now, we know …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
